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Exploiting the inhibition of host signaling pathways aiming for discovery of potential antiﬂaviviral
compounds is clearly a beneﬁcial strategy for the control of life-threatening diseases caused by ﬂavivi-
ruses. Here we describe the antiviral activity of the MEK1/2 inhibitor U0126 against Yellow fever virus
17D vaccine strain (YFV-17D). Infection of VERO cells with YFV-17D stimulates ERK1/2 phosphorylation
early during infection. Pharmacological inhibition of MEK1/2 through U0126 treatment of VERO cells
blockades not only the YFV-stimulated ERK1/2 phosphorylation, but also inhibits YFV replication by
99%. U0126 was also effective against dengue virus (DENV-2 and -3) and Saint-Louis encephalitis virus
(SLEV). Levels of NS4AB, as detected by immunoﬂuorescence, are diminished upon treatment with the
inhibitor, as well as the characteristic endoplasmic reticulum membrane invagination stimulated during
the infection. Though not protective, treatment of YFV-infected, adult BALB/c mice with U0126 resulted
in signiﬁcant reduction of virus titers in brains. Collectively, our data suggest the potential targeting of
the MEK1/2 kinase as a therapeutic tool against diseases caused by ﬂaviviruses such as yellow fever,
adverse events associated with yellow fever vaccination and dengue.
 2014 Elsevier B.V. All rights reserved.1. Introduction the genome, while the remaining of the genome encodes theYellow fever virus (YFV), the causative agent of Yellow Fever
(YF), is the prototypic member of the genus Flavivirus, family Flavi-
viridae. Two genera in this family contain major human pathogens,
including dengue (DENV), Saint-Louis encephalitis (SLEV), Japanese
encephalitis (JEV) and West Nile (WNV) viruses in the Flavivirus
genus and hepatitis C virus (HCV) in the Hepacivirus genus
(Lindenbach et al., 2013). The family comprises a group of posi-
tive-sense, single-stranded RNA viruses with a genome approxi-
mately 11 kb in length. The YFV genome encodes a polyprotein
from a single open-reading frame that is cleaved by host and virus
proteases into 10 polypeptides (Gardner and Ryman, 2010). The
structural proteins C, prM/M and E are encoded by the 50 end ofnon-structural (NS) proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B,
and NS5 which are associated with virus-host interactions, viral
assembly and replication (Fernandez-Garcia et al., 2009;
Lindenbach et al., 2013; Morais et al., 2013; Rice et al., 1985).
The urban YFV transmission is initiated through the bite of infected
Aedes aegypti mosquito to human. It is estimated that 900 million
people are at risk of infection at endemic zones, which include
tropical regions of Africa, Central and South America (Briand
et al., 2009; Gardner and Ryman, 2010). YF is a viral hemorrhagic
fever (VHF) that shares clinical features with other VHFs such as
Dengue hemorrhagic fever (DHF), Lassa fever, and Crimean-Congo
hemorrhagic fever, but is distinguished from the others VHFs by
the characteristic severe liver damage followed by jaundice. Its
lethality ranges from 20% to 50%. In humans, after a 3- to 6-day
incubation period, it is followed by the onset of symptoms which
vary from non-speciﬁc, such as fever and headache in mild cases,
to high fever and hemorrhagic manifestations with the character-
istic ‘‘black vomit’’ (hematemesis, gastrointestinal hemorrhage)
in the more severe form of the disease (Gardner and Ryman,
2010; Lindenbach et al., 2013).
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is available, severe adverse events associated with vaccination
have been recognized leading to complications such as neurotropic
and viscerotropic diseases (Bonaldo et al., 2014; Martin et al.,
2001; Vasconcelos et al., 2001). In addition, although potential
antiﬂavivirus compounds have been tested in vitro (Furuta et al.,
2013; Mastrangelo et al., 2012; Stahla-Beek et al., 2012), there is
no therapeutics currently available to treat clinically apparent YF
(Bray, 2008; De Clercq, 2013). Targeting of host cell signaling has
been proven useful to prospect antiviral agents, based on the fact
that, in order to ensure progeny generation and spread, viruses
manipulate diverse critical host signaling pathways (Andrade
et al., 2004; Pastorino et al., 2010) associated with survival/prolif-
eration (Soares et al., 2009) and cytoskeleton network and cell traf-
ﬁcking (Chu and Ng, 2004; Pereira et al., 2012).
Activation of the MEK1/2 [mitogen-activated protein kinase
(MAPK) extracellular signal-regulated kinase (ERK) kinase]/ERK1/
2 signaling pathway is involved in diverse cellular responses such
as motility, proliferation, differentiation and survival (Raman et al.,
2007). A number of RNA and DNA viruses relies on MEK/ERK sig-
nals in order to support a productive infection, including some ﬂa-
viviruses, such as including hepatitis C virus (Menzel et al., 2012;
Zhao et al., 2006, 2013), West Nile fever virus (Scherbik and
Brinton, 2010), Japanese encephalitis virus (Gupta et al., 2011;
Yang et al., 2010) and Dengue virus (Smith et al., 2014), making
this signaling pathway an attractive antiﬂaviviral therapeutic tar-
get. In this study we provide evidence both in vitro and in vivo that
the pharmacological inhibitor of MEK1/2 – U0126, presented an
antiviral efﬁcacy against other ﬂavivirus, YFV.2. Materials and methods
2.1. Cell culture, antibodies and chemicals
VERO E6 and BHK-21 cells were cultured in autoclaved Eagle’s
minimum essential medium (MEM, Auto Pow, Gibco, USA) supple-
mentedwith5% (v/v)heat-inactivated fetal bovineserum(FBS) (Cul-
tilab – Campinas, SP, Brazil), 200 mM Glutamin (Invitrogen – São
Paulo, Brazil), and antibiotics (40 lg/ml Gentamicin, 200 U/ml Pen-
icillinand1.5 lg/mlFungizone)and incubated in5%CO2at37 C.C6/
36 cellswere cultured in Leibowitz (L-15)medium(Gibco,USA) sup-
plemented with 5% heat-inactivated FBS plus the above antibiotics
and incubated at 28 C. Rabbit polyclonal anti-phospho-ERK1/2
(Thr202/Tyr204) and anti-PDI antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA). Mouse monoclonal anti-
b-actin antibody and DAPI (4,6-diamino-2-phenylindole) were pur-
chased from Sigma (São Paulo, Brazil). AlexaFluor 488-conjugated
anti-rabbit IgG and rhodamine-conjugated phalloidin were pur-
chased from Molecular Probes. The non-competitive inhibitor of
MEK1/2 U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenyl-
thio] butadiene), and PI3K inhibitor – LY294002 (2-morpholino-8-
phenyl-4H-1-benzopyran-4-one)werepurchased fromCell Signaling
Technology (Beverly, MA, USA). JNK inhibitor VIII – JNKi (N-(4-
Amino-5-cyano-6-ethoxypyridin-2-yl)-2-(2,5-dimethoxyphenyl)
acetamide), Akt inhibitor – Akt X (10-(40-(N-diethylamino)-butyl)-
2-chlorophenoxazine), and p38 MAPK inhibitor – SB203580 (4-
(4-ﬂuorophenyl)-2-(4-methylsulﬁnylphenyl)-5-(4-pyridyl)-imidazole)
were purchased from Calbiochem – Merck (Darmstadt, Germany).
Rabbit anti-YFVNS4ABantibodywas a generous gift fromDrCharles
Rice, Rockfeller University, USA.2.2. Viruses and viral infection
YFV strain 17D (vaccine strain) was propagated in VERO cells.
DENV-2 genotype III (PI-59/2006 – Piauí-59) (Figueiredo et al.,2008) and DENV-3 genotype I (MG-20/2004) (Ferreira et al.,
2010) were propagated in C6/36 cells. SLEV (BeH 355964) (De
Morais Bronzoni et al., 2005) was propagated in BHK-21 cells.
Brieﬂy, VERO, C6/36 or BHK-21 monolayers at 80–90% conﬂuence
were infected at a multiplicity of infection (MOI) of 0.01 in the
presence of 1% FBS. After 72 h post-infection (hpi) supernatants
were harvested and clariﬁed by centrifugation (900 g, 4 C,
15 min). Aliquots were stored at 80 C. The same procedure was
carried out with the supernatants of non-infected cells, which were
used as mock controls in the subsequent experiments. Procedure
for UV inactivation of virus stocks was described elsewhere (De
Magalhães et al., 2001). Viral infections were carried out with
serum-starved cells. Twelve hours prior to infection, cells grown
to 80–90% conﬂuence were starved with 1% FBS MEM. Cells were
then infected at the indicated MOI for the times shown. Cells were
treated with the indicated pharmacological inhibitor for 30 min
prior to viral infection and then incubated in its continued pres-
ence for the indicated times.
2.3. Virus infectivity assays
VERO or BHK-21 cells were cultured and starved as above at a
density of 5  105 cells per well, in a 6-well culture dish and then
infected. Infection of VERO cells (YFV) was carried out at an MOI of
1.0 for 6, 12, 24 and 48 h, and infection of BHK-21 cells (DENV and
SLEV) was carried out at an MOI of 1.0 for 48 h, either in the
absence (DMSO 0.06%) or in the presence of U0126 (15 lM), Akt-
X (15 lM), LY294002 (20 lM), JNK inhibitor VIII (4 lM) or
SB203580 (20 lM). At the indicated times, cultures (cells plus
medium) were frozen and thawed once. Virus was collected from
the supernatants after centrifugation and immediately assayed
for infectivity as described (Figueiredo et al., 2008). Each experi-
ment was run in triplicate and the results are reported as the aver-
age values. The data were conﬁrmed by three independent
experiments with very similar results.
2.4. Cytotoxicity assays
Conﬂuent 6-well dishes of VERO cells were treated with
increasing concentrations of U0126 (5, 10, 20 and 40 lM), of JNKi
VIII (0.4, 4 and 40 lM), of SB203580 (5, 10, 20 and 40 lM), of
LY294002 (5, 10, 20 and 40 lM), and of Akt X (3.75, 7.5, 15 and
20 lM). BHK-21 cells were treated with 15 lM of U0126. At 48 h,
an equal volume of Trypan Blue stain was added to the trypsin-
detached cells. VERO and BHK-21 cells were stained for 10 min
at room temperature and after that cells were observed for any evi-
dence of stain absorption (an indication of cellular membrane per-
meability and death). We found that P90% of the cells pretreated
with U0126 at 15 lM; JNKi at 4 lM; SB203580 at 20 lM and
LY294002 at 20 lM, were not stained. These concentrations were
then used throughout the experiments.
2.5. Electron microscopy
VERO cells were grown in 150-cm2 culture ﬂasks to 80–90%
conﬂuence and FBS-starved as described. Cells were treated with
DMSO (0.06%) or U0126 (15 lM) as described above and then
infected with YFV-17D at MOI of 1.0. Uninfected cells were treated
in the same way and used as controls. After 1, 24 and 48 hpi, cells
were washed twice with FBS-free MEM, ﬁxed with 2.5% glutaralde-
hyde grade I (Electron Microscopy Sciences, Germany) for 1 h at
room temperature (RT) and processed as described previously
(Pereira et al., 2012). Cells were examined using a Tecnai G2-Spirit
FEI 2006 transmission electron microscope operating at 80 kV at
the Microscopy Center, UFMG, Brazil. A quantitative analysis of
YFV morphogenesis intermediates was carried out. Three struc-
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ER-derived vesicle packets induced in the early stages of ﬂavivirus
morphogenesis; (ii) replication complex (RC)-containing vesicles,
vesicles encompassed in vesicle packets with the RC assembled
in their interior; and (iii) virions, contained in ER/golgi-derived
vesicles. Percents of each structure in the total amount of YFV mor-
phogenesis intermediates were calculated for each treatment and
time of infection.
2.6. RNA extraction, cDNA synthesis and quantitative PCR
Total RNA extraction was performed by using the TRIzol reagent
(Invitrogen) according to the manufacturer’s procedures. Comple-
mentary DNAs from () and (+) strands were reverse transcribed
with mFU1 and CFD2 Flavivirus-speciﬁc primers (Chao et al.,
2007), respectively, or without primers as a self-priming control.
Five hundred nanograms of primers and 2 lg of RNA were incu-
bated at 70 C for 5 min and then placed on ice. Complementary
DNA was synthesized with M-MLV Reverse Transcriptase (Pro-
mega) according to the manufacturer’s instructions. Quantitative
PCR (qPCR) was performed with the mFU1 and CFD2 primers. Each
reaction was performed by using the SYBR Green PCR Master Mix
(Applied Biosystems), 10 lM of forward and reverse primers and
1 lL of 1:3 diluted cDNA, in a Step ONE Real Time PCR System
(Applied Biosystems), following manufacturer’s recommendations.
The Relative Standard Curve method was used to analyze the data.
2.7. Immunoﬂuorescence microscopy
8  104 VERO cells were grown on coverslips in 24-well dishes,
FBS-starved for 12 h, and infected with YFV at an MOI of 1.0 in the
presence of DMSO (0.06%) or U0126 (15 lM) for 24 h. After, cells
were rinsed with cold PBS and ﬁxed with 4% paraformaldehyde
(PFA) in PBS for 10 min at room temperature (RT). Cells were
stained with speciﬁc primary antibodies: rabbit anti-YFV NS4A/B
(1:1000) or rabbit anti-PDI (1:50), as described previously
(Pereira et al., 2012). AlexaFluor 488-conjugated anti-rabbit IgG
(1:400) was used as secondary antibody. Fluorescently labeled
cells were visualized using a Zeiss LSM 510 META confocal laser
scanning microscope at the Center for the Acquisition and Process-
ing of Images (CAPI/UFMG). Images were processed with ImageJ
(NIH).
2.8. Western blotting
VERO cells were grown in 25-cm2 ﬂasks, FBS-starved and left
uninfected or infected with YFV-17D at an MOI of 1.0 for the indi-
cated times, in the absence or presence of U0126. Cells were then
washed twice with cold PBS. Whole cell protein extracts and
immunoblotting were prepared as described (Pereira et al.,
2012). Thirty-ﬁve micrograms of the cell lysate per sample were
separated by electrophoresis on a 10% SDS–polyacrylamide gel
and then transferred onto nitrocellulose membranes. Immunoblot-
ting was performed with anti-phospho-ERK1/2 (1:1000) or anti-b-
actin (1:3000), and horseradish peroxidase-conjugated secondary
anti-rabbit IgG (1:3000) or anti-mouse IgG (1:3000). Immunoreac-
tive bands were visualized by using ECL Plus detection system as
described in the manufacturer’s instructions (GE Healthcare, UK).
2.9. In vivo infection
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals,
NIH, USA. The protocol was approved by the Institutional Animal
Care and Use Ethics Committee at UFMG (Assurance Number:
80/2011). All inoculation and experimental manipulation wereperformed under anesthesia that was induced and maintained
with ketamine hydrochloride and xylazine. Male BALB/c mice were
obtained from UFMG’s animal facility and kept in an ABSL2 at the
Department of Microbiology, UFMG. At age of 8 week-old, mice
were intravenously injected with 30 lg of U0126 or vehicle (2.5%
Dimethyl-Sulfoxide, 10% Ethanol, 5% Cremophor EL and 10% PEG-
400 in saline) through the tail vein. One day after starting the
U0126 treatment, inoculum containing 103 PFU of YFV-17D
(10 lL) was administered via intracranial injection to mice.
Mock-infected animals were injected with the same volume of
the supernatant of mock-infected VERO cells. Daily, animals
received intravenous single dose-injection of U0126 (30 lg/ani-
mal/day) or vehicle and were monitored for body weight loss
and disease appearance. Once the animals reached 25% of body
weight loss or presented lower limbs paralysis they received a
lethal dose of anesthetics (300 mg/kg Ketamine, 30 mg/kg Xyla-
zine), followed by cervical dislocation. Percent mortality and
weight loss were calculated, and brains, spleens and livers were
collected for further analysis. Brain halves, spleen and liver of each
animal were individually macerated in MEM containing 2% FBS,
clariﬁed by centrifugation (900 g, 5 min, 4 C) and the supernatants
were inoculated onto VERO cell monolayers for virus titration, as
described above. For in vivo evaluation of ERK1/2 phosphorylation,
mice brain halves were individually macerated in cell lysis buffer,
containing proteases and phosphatases inhibitors, and the total
protein extract was prepared and quantiﬁed as described. Pools
of whole brain protein extracts of 5 animals were prepared for each
group (5 lg/animal) for Western blot analysis.
2.10. Densitometric analysis
Phosphorylated-ERK1/2 was quantiﬁed using densitometric
analysis tool from ImageJ software (NIH) and the levels were nor-
malized to the levels of b-actin in the same sample. The changes in
protein phosphorylation with respect to control values were esti-
mated. The results were expressed as the phospho-ERK to b-actin
ratio measured in arbitrary units.
2.11. Statistics
Data gathered in animal studies were analyzed by Mantel–Cox
survival analysis and Two-way Anova with Bonferroni post-test for
weight loss curves. Virus yield means in brains of drug treated ver-
sus non-treated animals were compared through Student’s t test.3. Results
3.1. MEK/ERK pathway inhibition affects YFV replication
We initially tested speciﬁc cell signaling pathways inhibitors,
such as MEK/ERK (U0126 – 15 lM), Akt (inhibitor-X – 15 lM),
PI3K (LY294002 – 20 lM), JNK (inhibitor VIII – 4 lM) and p38
MAPK (SB203580 – 20 lM). VERO cells were treated with the indi-
cated concentration of inhibitor for 30 min prior to infection with
YFV at an MOI of 1.0 for 48 h. After that, YFV-containing superna-
tant was collected and assayed for infectivity. As shown in Fig. 1A,
U0126 reduced virus replication more effectively. While U0126
caused about 2-log10 units inhibition of YFV replication, the other
pharmacological inhibitors tested did not inhibit YFV replication
with similar effectiveness. Further, we analyzed whether viral
growth inhibition was dose-dependent. The infections were car-
ried out in concentrations of U0126 ranging from 5 to 40 lM and
then the viral titers were assayed, showing that viral growth inhi-
bition is dose-dependent (Fig. 1B). Thus, we conclude that the dis-
turbance in MEK/ERK signaling is deleterious for YFV replication. In
Fig. 1. MEK/ERK plays a speciﬁc role in YFV replication. Cells were either left untreated, or treated for 30 min with the indicated pharmacological inhibitor prior to virus
infection and then infected with YFV, DENV or SLEV at an MOI of 1.0 either in the absence or in the continued presence of the inhibitor for 48 h. Viruses were then collected
and their infectivity determined. (A) Effect of diverse pharmacological inhibitors on YFV replication. VERO cells were incubated with the speciﬁc pharmacological inhibitors:
MEK/ERK (U0126 – 15 lM), Akt (Akti X – 15 lM), PI3K (LY294002 – 20 lM), JNK1/2 (JNKi VIII – 4 lM) and p38 MAPK (SB203580 – 20 lM), for 48 h. (B) Effect of U0126 on YFV
replication is dose-dependent. VERO cells were infected with YFV-17D at an MOI of 1.0 for 48 h in the absence or in the continued presence of the MEK/ERK inhibitor (U0126)
at 5, 10, 20 and 40 lM, for 48 h. Viral yield (PFU/mL) is indicated by black bars. Cell viability in the presence of U0126 for 48 h, as assessed by trypan blue exclusion, is
expressed as the percent (%) of viable cells and is indicated by the black dots. (C) Effect of U0126 on DENV-2/-3 and SLEV replication. BHK21 cells were infected with DENV-2,
DENV-3 or SLEV at an MOI of 1.0 for 48 h either in the absence or in the continued presence of U0126 – 15 lM. (D) YFV stimulates ERK1/2 phosphorylation. VERO cells were
either mock-infected or infected with YFV at an MOI of 1.0 for the indicated times. Infected-cell lysates were subjected to western blot and probed with anti-phospho-ERK1/2
(Thr202/Tyr204-P) antibody (upper panel) or with anti-b actin antibody (lower panel), used as a loading control. Cells were infected either in the absence (lanes 1–3, 6–8, 10–
12, 14–16, 18–20) or in the presence of U0126 (15 lM) (lanes 4, 5, 9, 13, 17 and 21). Cells were also exposed to UV-inactivated YFV (lanes 3, 5, 8, 12, 16 and 20). The levels of
phosphorylated ERK1/2 were quantiﬁed by densitometric analysis and the phospho-ERK/b-actin ratio (arbitrary units) is shown. The molecular masses (kDa) are indicated on
the left. (E) The MEK/ERK signaling pathway is required for viral replication. VERO cells were infected with YFV at an MOI of 1.0 for 6, 12, 24 and 48 h, either in the absence or
in the presence of U0126 (15 lM). Virus was collected and their infectivity assayed. Similar results were obtained in three independent experiments.
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Fig. 2. The MEK/ERK signaling pathway is required for YFV replication. (A) Cells were infected with YFV at an MOI 1.0 for 48 h and treated with the U0126 (15 lM) according
to the diagram depicted in the right panel. Heavy and dotted lines: in the presence or in the absence of U0126, respectively. Virus was collected and its infectivity assayed. The
data are representative of three independent experiments with similar results. (B) Removal of U0126 releases YFV-stimulated MEK/ERK pathway. Western blot analysis
carried out with whole cell extracts of mock-infected (lanes 1–3) or infected with YFV at an MOI of 1.0 for the indicated times (lanes 4–6), either in the absence (lanes 1, 4) or
in the presence of U0126 (lanes 2, 3, 5,6). Cells were washed after 2.5 h of U0126 treatment (lanes 3 and 6) and the infection was allowed to continue for additional 30 min.
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restricted to YFV, its effect on the replication of DENV and SLEV
was tested further. To that end BHK-21 cells were treated with
U0126 at 15 lM for 30 min. prior to infection with DENV-2,
DENV-3 and SLEV at an MOI of 1.0 for 48 h. After that, DENV- or
SLEV-containing supernatants were collected and assayed for
infectivity. As shown in Fig. 1C, U0126 presented a broad antiﬂa-
viviral effect, affecting not only YFV, but other members of the Fla-
vivirus genus such as DENV and SLEV.
Next, we examined MEK/ERK stimulation upon YFV infection
and whether it might depend on YFV replication. To approach that,
VERO cells were exposed to the UV-inactivated YFV, or infected
with YFV at an MOI of 1.0 either in the presence or absence of
U0126 for the indicated times. Fig. 1D shows that ERK1/2 phosphor-
ylation upon YFV infection is an early event starting 15 min post-
infection (lane 2), prolonged up to 6 hpi (lane 15) and declined after
that time (lane 19). Our data also demonstrates that replication
competent virus is not an essential requirement for ERK1/2 activa-
tion, since the levels of ERK1/2 phosphorylation (lanes 3, 8, 12, and
16) with UV-inactivated YFV were about the same as those veriﬁed
with the non-inactivated virus (lanes 2, 7, 11 and 15).
To get some insight to what extent U0126 would impact the YFV
life cycle, VERO cells were virus-infected at an MOI of 1.0 for 6, 12,
24 and 48 h either in continued presence or absence of U0126
(15 lM). After that, virus was collected and assayed for infectivity.
Our data are consistent with the idea that MEK/ERK plays, in fact, a
decisive role in YFV replication, since the block imposed by the
inhibitor affected the whole virus infective cycle (Fig. 1E).
3.2. The MEK/ERK signaling pathway is required for YFV replication
Next, we designed an experiment in the attempt to deﬁne to
what extent MEK/ERK could affect YFV replication, depicted atFig. 2A. Cells were left untreated (lane 1) or incubated with
U0126 (15 lM) prior to (lanes 2, 3, 5 and 7) or after (lanes 4, 6
and 8) YFV infection at an MOI of 1.0 for 48 h. Virus was then col-
lected and assayed for infectivity. The experiments were carried
out at the time-frame where YFV-stimulated MEK/ERK activation
was veriﬁed (Fig. 1D). As demonstrated in Fig. 2A, when the block
that interrupts the signal transmission initiated by MEK/ERK (lanes
3, 5 and 7) is released, YFV replicates to the same extent as veriﬁed
with the control (lane 1). Moreover, whenever U0126 is added
after the ongoing infection, YFV titers are similar to that veriﬁed
when the infection is carried out in the continued presence of
the inhibitor (lane 2). To conﬁrm that the signal transmission by
MEK/ERK is released after removing U0126, VERO cells were either
mock-infected or infected with YFV in the presence or absence of
U0126 as shown in Fig. 2B. Treatment with the inhibitor was inter-
rupted by washing the cells with fresh media and the infection was
allowed to proceed for further 30 min, as indicated (lanes 3 and 6).
Cell extracts were then collected, subjected to Western blot and
probed for phosphorylated ERK1/2. Our data shows that in contrast
to the observed inhibition of phospho-ERK1/2 upon infection in the
presence of U0126 (lane 5), after removing the inhibitor YFV is able
to stimulate the kinases (lane 6). Although just one time is shown,
the same result was also veriﬁed with the other investigated times
up to 12 hpi (data not shown).
3.3. Inhibition of MEK/ERK affects YFV genome replication
Considering that the UV-inactivated YFV is still able to stimu-
late MEK/ERK, we ﬁrstly investigated whether the signal transmis-
sion was altered at the virus adsorption/entry step. To address that,
cells were infected with YFV at an MOI of 1.0 either in the absence
or presence of U0126 (15 lM) for 1 h. Cells were then ﬁxed and
prepared for electron microscopy (Fig. 3A). Results obtained here
Fig. 3. Inhibition of MEK/ERK leads to decreased YFV genome replication. (A) YFV entry is not affected by MEK/ERK interruption. VERO cells were left uninfected (a) or
infected with YFV (b, c) at an MOI of 1.0 for 1 h, either in the absence (a, b) or in the presence of U0126 (15 lM) (c). Cells were then ﬁxed and prepared for transmission
electron microscopy. Electron micrographs are shown with their scale indicated by the bars. Details show YFV virions (arrows) entering into the cell through endocytosis
(arrowheads). Abbreviations:M, mitochondria, ER, endoplasmic reticulum. G, Golgi complex. Data is representative of two independent experiments with identical results. (B)
Time-course of viral RNA (+) and () synthesis upon YFV infection. Cells were infected with YFV at an MOI of 1.0 for 3, 6, 9, 18, 30 and 48 h (B), or for 18, 24 and 48 h either in
the absence or in the presence of U0126 (15 lM) (C). RNA was then isolated and subjected to quantitative RT-PCR with speciﬁc primers.
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YFV entry into cells (Fig. 3A – panel b compared to panel c).
We then raised the question whether the MEK/ERK blockade
was affecting the YFV genome replication. To approach this ques-
tion, VERO cells were infected with YFV at an MOI of 1.0 for the
times shown and total RNA was isolated and subjected to quanti-
tative RT-PCR with speciﬁc primers for both the (+) and () RNA
strands.
Fig. 3B depicts the relative quantiﬁcation of both plus and
minus RNA strands during the time-course of YFV infection. RNA
(+) and () strand levels remain steady during the early stages of
infection (3–9 hpi). After 9 hpi, there is an exponential increment
in the accumulation of both strands. RNA (+) strand accumulation
is increased approximately 100 times after 18 hpi and reaches the
peak at 30 hpi. RNA () strand synthesis follows similar kinetics,
even though its quantiﬁcation is commonly 2-log10 units lower
than RNA (+) strand over time.
Although U0126 treatment does not block, it signiﬁcantly
impairs RNA (+) strand synthesis as demonstrated in Fig. 3C. In
the presence of U0126, levels of RNA (+) strand are reduced
approximately 51.1%, 73.8% (P < 0.01) and 50.2% (P < 0.001), at
18, 24 and 48 hpi, respectively. In the same conditions, RNA ()
strand synthesis levels are diminished 23.2%, 43.56% and 40.4%.
Together, these observations suggest that the blockade of MEK/
ERK pathway signiﬁcantly affects YFV-17D genome replication.
However, the inhibition levels observed here may not be sufﬁcientto account for a reduction of 2-log10 units in YFV-17D viral yield
in the presence of U0126. Additional downstream targets of MEK/
ERK pathway inhibited by U0126 remain to be further addressed.
3.4. MEK/ERK inhibition affects the accumulation of YFV NS4AB and
endoplasmic reticulum resident protein PDI
To gain insight into the mechanism(s) underlying the decreased
viral yield upon treatment with U0126, we investigated whether
YFV NS4AB protein accumulation was affected following the treat-
ment with the inhibitor. VERO cells were mock-infected or infected
with YFV either in the presence or absence of U0126 (15 lM), at an
MOI of 1.0 for 24 h and NS4AB expression was analyzed by immu-
noﬂuorescence. As shown in Fig. 4A, detection of NS4AB protein
was impaired upon treatment with U0126 (compare panels b
and c).
Flavivirus genome replication occurs at the rough endoplasmic
reticulum (rER) within vesicle packets, a site where genome repli-
cation complex is assembled in order to maximize virus replication
(Mackenzie and Westaway, 2001; Welsch et al., 2009). We then
investigated whether the interruption of MEK/ERK signaling was
also associated with altered organization of rER. To approach that,
VERO cells were mock-infected or infected with YFV (MOI of 1.0)
for 24 h either in the absence or presence of U0126 (Fig. 4B). Cells
were ﬁxed and stained for Protein Disulﬁde Isomerase (PDI), an ER-
resident protein (panels a, d, g, j) and rhodamine-conjugated phal-
Fig. 4. MEK/ERK is required for detection of viral NS4AB and host PDI proteins.
VERO cells were grown onto coverslips and infected with YFV at an MOI of 1.0 for
24 h, or left uninfected. Where indicated, VERO cells were infected with YFV in the
presence of U0126 (15 lM) for 24 h. Cells were then ﬁxed, permeabilized and
stained with an anti-NS4AB antibody (panels a, c, e) and DAPI (panels b, d, f) (A), or
stained with anti-Protein Disulﬁde Isomerase (PDI) antibody (panels a, d, g, j) and
rhodamine-conjugated phalloidin (actin cytoskeleton – panels b, e, h, k) (B). The
panels c, f, i, and l in B depict the merge of PDI and actin stainings. The images were
visualized by confocal microscopy.
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ized by confocal microscopy. As observed, while an accentuated
increase in PDI accumulation is evident at the perinuclear region
and cytoplasm of YFV-infected cells (panels g–i), in contrast, PDI
levels in U0126-treated cells (panels j–l) were similar to those
observed in mock-infected cells (panels a–c).3.5. Blockade of MEK/ERK pathway affects YFV morphogenesis
We then asked whether the blockade of MEK/ERK would affect
YFV morphogenesis. Therefore, VERO cells were infected with YFVas described, in either the absence or presence of U0126. Cells were
then prepared and analyzed by electron microscopy (Fig. 5A). As
observed, YFV infection stimulates the invagination of the ER-
derived membranes leading to formation of diverse vesicle packets
(VP) (Fig. 5A – panels b and e). The electron-dense material
observed within the VPs is thought to contain the Replication Com-
plex (RC) and serve as sites for the viral RNA replication (panel f –
arrowhead) (Gillespie et al., 2010; Welsch et al., 2009). While these
VPs are consistently found in untreated and YFV-infected cells
(inset from panel e highlighted in panel f), in remarkable contrast,
they are barely detected at 24 h and just scarcely veriﬁed at 48 h
when the infection is carried out in the presence of U0126
(Fig. 5A – panel h). In this circumstance empty vesicles accumulate
(panel h and enlarged inset in i). A morphometric analysis was car-
ried out and the data is presented in Fig. 5B.3.6. In vivo antiviral activity
Next, we sought to evaluate the in vivo antiviral potential of the
MEK1/2 inhibitor U0126. Eight-week old BALB/c mice were
infected with 103 PFU of the YFV-17D through intracranial injec-
tion. Animals were treated with 30 lg of U0126, or vehicle only,
through intravenous injection in the tail vein one day prior infec-
tion and daily throughout the course of infection. Intravenous
administration of U0126 in mouse models has been described else-
where (Mori et al., 2002; Namura et al., 2001; Wang et al., 2004).
Despite the in vitro efﬁciency of U0126 in halting YFV replica-
tion in VERO cells, treatment of YFV-infected BALB/c mice with
U0126 was not protective against infection, given all YFV-infected
animals died within 9 days after challenge. Also, there were no sig-
niﬁcant differences in weight loss kinetics or survival between
YFV-infected animals, treated or not with MEK1/2 inhibitor
U0126 (not shown). Nonetheless when animals reached 25% of
body weight loss individual tissues such as liver, spleen and brain
were collected and both viral load and ERK1/2 phosphorylation
were determined. However, we were unable to detect YFV replica-
tion through plaque assay in any tissues other than brains. Inter-
estingly, YFV titers in brains of U0126-treated animals after 9 dpi
(6.76  106 ± 1.51  106 PFU/g, n = 9) were signiﬁcantly lower than
those observed in vehicle-only treated mice (1.47  107 ± -
3.36  106 PFU/g, n = 8) (reduction of 54.3%, p 6 0.05) (Fig. 6A).
Accordingly, Fig. 6B demonstrates that treatment of YFV-infected
mice with U0126 reduces the levels of ERK1/2 phosphorylation
in brains by approximately 48.8% (Fig. 6B, lane 3) in comparison
with the levels in vehicle-only treated mice (Fig. 6B, lane 2). These
results are in accordance with the in vitro observed effect(s) of
U0126 over YFV replication and reinforces the potential therapeu-
tic employment of MEK1/2 inhibitors as anti-YFV drugs.4. Discussion
In an attempt to ﬁnd chemicals with antiﬂaviviral activity, we
carried out the infection of VERO cells with YFV-17D in presence
of a series of pharmacological inhibitors targeting host signaling
pathways that could be important to the virus replication cycle.
Speciﬁc inhibitors of MEK1/2 (U0126), JNK1/2-SAPK (JNK inhibitor
VIII), p38 MAPK (SB203580), PI3K (LY294002) and Akt/PKB (Akt
inhibitor X) were then tested as potential antiviral and U0126
proved to convey greatest efﬁciency in inhibition of YFV
(Fig. 1A). A signiﬁcant inhibition of approximately 2-log10 units
in YFV yield was observed in the presence of U0126, in a dose-
dependent manner (Fig. 1B).
The involvement of MEK/ERK pathway has already been
reported during the infection with several members of Flaviviridae
family, including hepatitis C virus (Menzel et al., 2012; Zhao et al.,
Fig. 5. Blockade of MEK/ERK pathway affects YFV morphogenesis. (A) Representative micrographs of the effects of U0126 on YFV-17D morphogenesis. FBS-starved VERO cells
were treated with DMSO (a–c, e, f) or U0126 (d, g–i) and infected with YFV-17D at an MOI of 1.0 (b, c, e–i), or left uninfected as controls (a, d). After 24 (a–d, g) or 48 hpi (e, f, h,
i), cells were processed for transmission electron microscopy. Micrographs c, f, and i are higher magniﬁcation insets of micrographs b, e, and h, respectively. Electron
micrographs are shown with their scale indicated by the bars. Abbreviations:M, mitochondria; Nu, nucleus; VP, vesicle packets; v, vesicles containing virions; arrow indicates
a typical YFV virion; arrowheads indicate replication complexes (RC) inside vesicles; asterisks (⁄) indicate typical ER organization. (B) Graphical representation of the percents
of YFV morphogenesis intermediates, according to the accompanying panel. Alongside the bars are the numbers of YFV morphogenesis intermediates counted in each sample
(n = 10 cells). Data is representative of two independent experiments with similar results.
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Japanese encephalitis virus (Gupta et al., 2011; Yang et al., 2010)
and Dengue virus (Smith et al., 2014), thus emphasizing its impor-
tant role played in ﬂaviviruses’ replication. Here we showed that
YFV stimulates the activation of MEK/ERK pathway in VERO cells
from as early as 15 min. post-infection up to 6 hpi (Fig. 1D). Inter-
estingly, infection carried out with UV-inactivated YFV is still able
to stimulate ERK1/2 phosphorylation (Fig. 1D), but the same was
not observed for heat-inactivated YFV (data not shown). A previous
report showed that UV-inactivated WNV induces an early transient
activation ERK1/2, although sustained activation of these kinases
required replication competent viruses (Scherbik and Brinton,
2010). More recently, a study described that treatment of DC-SIGN
expressing cells with soluble HCV E2 protein is responsible for a
rapid and sustained activation of MEK/ERK pathway (Zhao et al.,
2013). Over the last decade several reports showed that HCV E2
protein is actively responsible for MAPK stimulation, which mightsupport progression of disease and pathogenesis associated with
HCV (Mazzocca et al., 2005; Zhao et al., 2005, 2006, 2013).
Together, these observations demonstrate that structural compo-
nents of ﬂaviviruses accomplish important roles in initial steps of
host-virus interaction.
Considering that a signiﬁcant decrease in viral titers was veri-
ﬁed only if the drug is continuously present or added to an ongoing
infection (Fig. 2A) and that U0126 inhibition of MEK1 and MEK2
catalytic activity is reversible (Favata et al., 1998), that could
explain why the removal of the inhibitor would enable YFV to re-
induce ERK1/2 phosphorylation (Fig. 2C). However, the mechanis-
tic details underlying U0126 reversible effects on YFV replication
requires further investigation.
Our data consistently shows that U0126 did not affect YFV vir-
ion entry into host cell (Fig. 3A). We also observed that U0126
treatment during adsorption at 4 C does not alter either YFV entry
or YFV replication (data not shown). Flavivirus entry by clathrin-
Fig. 6. Reduction of virus titers in brains of YFV-infected BALB/c treated with U0126. Adult BALB/c mice were injected in the tail vein with 30 lg of U0126, or vehicle, one day
prior and daily after intracranial inoculation with 103 PFU of YFV-17D. Control groups received the same volume of VERO cells supernatant. Animals were monitored for
disease signs and loss of weight and were euthanized when they reached the threshold of 25% body weight loss or presented lower limbs paralysis. (A) YFV virus production
in individual brains was determined through plaque assay in VERO cells. The graph represents the YFV virus yield in individual brains of untreated (YFV + vehicle) and U0126
treated mice. The means of virus yield were statistically analyzed with Student’s t test (p = 0.0274). (B) Western blot analysis of ERK1/2 phosphorylation in brains of
uninfected mice (lane 1), YFV-infected and untreated (YFV + vehicle – lane 2) and YFV-infected and treated with U0126 (YFV + U0126 – lane 3). Protein extracts of mice brain
halves were prepared and quantiﬁed as described. Pools of whole brain protein extracts of 5 animals were prepared for each group (5 lg/animal) for western blot analysis.
The levels of phosphorylated ERK1/2 were quantiﬁed by densitometric analysis and the phospho-ERK/b-actin ratio (arbitrary units) is shown. The molecular masses (kDa) are
indicated in the left.
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dence (Pierson and Kielian, 2012) and it has been shown that the
classical clathrin-dependent endocytic pathway seems to be resis-
tant to disruption of MEK/ERK signaling (Robertson et al., 2006).
Our ﬁndings are in line with these observations and demonstrate
that signaling through MEK/ERK is not required for YFV entry.
We showed here that treatment of YFV-infected cells with
U0126 does not blockade, but signiﬁcantly impairs, the accumula-
tion levels of positive RNA strands at late stages of infection
(Fig. 3C). Instead, accumulation of NS4A/B protein after 24 hpi is
untraceable in YFV-infected cells treated with U0126 (Fig. 4A).
Since generation of NS proteins is a prerequisite for RNA replica-
tion, we hypothesize that either canonical cap-dependent or non-
canonical internal ribosome entry site (IRES)-independent transla-
tion mechanisms are somehow functional in U0126-treated cells.
The co-expression of both NS4A and NS4B proteins, concomitant
with other NS proteins, is required for the formation of character-
istic membrane structures induced by ﬂavivirus infection
(Roosendaal et al., 2006; Miller et al., 2007). These virus-induced
membranes termed paracrystalline array, convoluted membranes
and vesicle packets all have speciﬁc functions during ﬂavivirus
genome replication (Lindenbach et al., 2013; Gillespie et al.,
2010; Welsch et al., 2009). Therefore, the reduction in accumula-
tion of NS4A/B protein in the presence of U0126 strongly suggests
that inhibition of MEK1/2 somehow disrupts YFV-induced mem-
brane rearrangement. Actually, VERO cells infected with YFV and
treated with U0126 presented with decreased staining for the ER
marker PDI (Fig. 4B – panels j–l) when compared to untreated,
YFV-infected VERO cells (Fig. 4B – panels g–i) (Op De Beeck
et al., 2004). Consistently, our electron microscopy analysis corrob-
orates the defects in YFV-induced ultrastructural changes of mem-
branes in infected cells treated with U0126 (Fig. 5A – panel h
compared to panels b/e). Together, these experimental observa-
tions demonstrate that disruption of MEK/ERK signaling affects at
least three critical YFV-induced intracellular events: NS proteins
accumulation, membrane rearrangements and genome replication.
It has been shown that both HCV and DENV requires group IVA
phospholipase A2 (PLA2G4A) for assembly of highly infectious
progeny, whose lipolysis-dependent enzymatic activity is underMEK/ERK regulation (Menzel et al., 2012). Whether PLA2G4A is
also a downstream target of MEK/ERK upon YFV infection is an
interesting issue that remains to be further investigated.
Finally, the observed antiviral activity conveyed by U0126 treat-
ment suggested the potential therapeutic use of MEK1/2 inhibitors
in the treatment of diseases caused by ﬂaviviruses. Even though
the protocol used in this study was not protective, since we did
not observe differences in morbidity and survival rates between
animals challenged with YFV and treated or not with U0126, the
observation that YFV titers are signiﬁcantly reduced in the brains
of individuals treated with U0126 is remarkable (Fig. 6). These
results corroborate the in vitro analysis, in which MEK/ERK disrup-
tion affects YFV replication.
U0126 has been largely employed to investigate the roles of
MEK/ERK in viral infections, cancer and other pathological pro-
cesses, but this drug could not be further developed for clinical
use due to pharmacological limitations, such as low oral bioavail-
ability (Planz, 2013). However, intravenous injection (IV) of
U0126 in mouse models was found to be protective against brain
injuries, such as ischemia and physical trauma (Namura et al.,
2001; Mori et al., 2002; Wang et al., 2004), demonstrating the
availability of U0126 in the brain. MEK1/2 inhibition was also pro-
tective in mice challenged with inﬂuenza virus upon treatment
with U0126 by inhalation (IN) (Droebner et al., 2011) or by intra-
peritoneal injection (IP) (Pinto et al., 2011). All treatment routes
(IV, IN or IP) were able to reduce ERK1/2 phosphorylation in animal
tissues, as observed in this study (Fig. 6B), and did not cause any
gross physiological alteration in treated mice (Droebner et al.,
2011; Namura et al., 2001; Mori et al., 2002; Pinto et al., 2011;
Wang et al., 2004). Moreover, other small molecule inhibitors of
MEK/ERK are under development for clinical use, with better phar-
macological performance, and can be tested for their efﬁcacy
against ﬂavivirus infections (Planz, 2013).
5. Conclusions
In conclusion, our results suggest the use of MEK1/2 as a poten-
tial therapeutic target for the development of antivirals against ﬂa-
viviruses, and U0126 as a potential lead for the design of such
J.D. Albarnaz et al. / Antiviral Research 111 (2014) 82–92 91antiﬂaviviral therapeutics. Our study also highlights the need to
continue pursuing better strategies for YFV infection control as
well as alternative YFV mouse models and routes for drug delivery
in order to foster our search for antiviral agents.
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